Skip to main content
Landherr_Laszlo_Primer_majdaganatok

 

Irodalom:
1. Adam R, Wicherts DA.et al: Complete pathologic response after preoperative chemotherapy for colorectal
liver metastases: myth or reality? J Clin Oncol. 2008.Apr 1:26(10):1535-41.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 310
A máj 311
2. Denecke T, Lopez Hamminen E.: brachytherapy of liver metastases. Recent Results Cancer Res. 2008;
177:95-104.
3. Ducreux M, Raoul JL. et al: High-dose irinotecan plus LVSFU2 or simplified LV5FU (HD-FOLFIRI)
for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Oncology.2008;74(1-2):17-24.
4. Giusti RM, Shastri K.et al: Food and Drug Administration approval: panitumumab for carcinoma with
progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Clin Cancer Res. 2008.Mar 1;14(5):1296-302.
5. Jakobs TF, Hoffmann RT, Dehm K. et al: Hepatic yttrium-90 radioembolization of chemoterapy-refractory
colorectal cancer liver metastases. J Vase Interv Radio. 2008 Aug;19(9):1187-95.
6. Kennedy AS, Dezarn WA.et al: Radioembolization for unresectable neuroendocrine hepatic metastases
using resin 90Y-micropheres early results in 148 patients. Am J Clin Oncol. 2008.Jun;31(3):271-9.
7. King J, Quinn R.et al: Radioembolization with selective internal radiation microspheres for for
neuroendocrine liver metastases. Cancer. 2008.Sep 1;113(5):921-9.
8. Knox JJ, Gill s. et al: A phase II and pharmacokinetic study of SB-715992, in patients with metastatic
hepatocellular carcinoma a study of the National Cancer Institute of Canada Clinical Trials Group
(NCIC CTG IND.168) Invest New Drugs. 2008.Jun;26(3):265-72.
9. Mitry E, Fields AL. et al: Adjuvant chemoterapy after potentially curative resection of metastases from
colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008.Oct 20;26(30):4906-11.
10. Neyns B, Aerts M. et al: Cetuximab with hepatic arterial infusion of chemoterapy for the treatment of
colorectal cancer liver metastases. Anticancer Res. 2008.Jul-Aug;28(4C):2459-67.
11. Neyns B, Aerts M. et al: Cetuximab with hepatic arterial infusion of chemoterapy for the treatment of
colorectal cancer liver metastases. Anticancer Res. 2008.Jul-Aug;28(4C):2459-67.
12. Nordlinger B, Sorbye H.et al: Perioperative chemoterapy with FOLFOX-4 and surgery versus surgery
alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983) a
randomised controlled trial. Lancet. 2008.Mar 22;371(9617):1007-16.
13. Pech M, Wieners G, Kryza R.et al: CT-guided brachytherapy (CTGB) versus interstitial laser ablation
(ILT) of colorectal liver metastases an intraindividual metched-pair analysis. Strablenther Onkol. 2008
Jun;184(6):302-6.
14. Price TJ, Townsend A, Yttrium: 90 microphere selective internal radiation tratment of hepatic colorectal
metastases. Arch Surg. 2008. Mar;143(3):313-4.
15. Salem R, Parikh P. et al: Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy
with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008.
Oct;31(5):431-8.
16. Scott LC, Yao JC.et al: A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of
locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer
Chemother Pharmacol 2009. Ja;53(2):363-70.
17. Tan MC, Castaldo ET.et al: A prognostic system applicable to patients with resectable liver metastases
from colorectal carcinoma staged by positron emission tomography with (18 F) fluoro-2-deoxy-D-glucose:
role of primary tumor variables. J.Am Coll Surg. 2008.May; 206(5):857-68., discussion 868-9.
18. Tan MC, Castaldo ET.et al: A prognostic system applicable to patients with resectable liver metastases
from colorectal carcinoma staged by positron emission tomography with (18F) fluoro-2-deoxy-D-glucose:
role of primary tumor variables. J AnColl Surg. 2008.May;206(5):857-68. Discussion 868-9.
19. Topkan E, Onal HC, Yavuz MN.: Managing liver metastases with conformal radiation therapy. J Support
Gastro 2009.qxd 5/9/2009 1:42 PM Page 311
312 Gastro Update 2009
Oncol. 2008 Jan;6(1):9-13,15.
20. Van lersel LB, Hoekman EJ. et al: Isolated hepatic perfusion with 200 mg melphalan for advanced
noncolorectal liver metastases. Ann Surg.Oncol. 2008.Jul;15(7):1891-8.
21. Xu KC, Niu LZ. et al: Percutaneous cryosurgery for the treatment of hepatic colorectal metastases.
World J Gastroenterol. 2008.Mar 7;14(9):1430-6.
22. Xu KC, Niu LZ. Et al: Percutaneous cryosurgery for the treatment of hepatic colorectal metastases.
World J Gastroenterol. 2008.Mar 7;14(9):1430-6.
23. Xu KC, Niu LZ.et. al: Percutaneous cryosurgery for the treatment of hepatic colorectal metastases.
World J Gastroenterol. 2008.Mar 7;14(9):1430-6.
24. Ychou M, Azria D. et al: Adjuvant radioimmunotherapy trial with iodine-131-labeled anti carcinoembryonic
antigen monoclonal antibody F6 F (ab’)2 after resection of liver metastases from colorectal cancer. Clin
Cancer Res. 2008.Jun 1;14(11):3487-93.
25. Wittig A, Malago M, Collette L. et al: Uptake of two 10B-compounds in liver metastases of colorectal
adenocarcinoma for extracorporal irradiation with boron neutron capture therapy (HORTC Trial 11001).
Int J Cancer. 2008 Mar 1;123(5):1164-71.